My concern, as you know, is that the human H1N1 that's circulating regularly is resistant to Tamiflu, and a lot of it is perhaps even resistant to Relenza. Where is the money coming from for the research for new antivirals? A real strategy would be trying to get ahead of the curve. Are we able, with cuts to CIHR, with cuts to everywhere we know, to have a national antiviral strategy that will give us what we need should this new and more severe virus in the fall end up resistant to the two drugs we already have?
On May 14th, 2009. See this statement in context.